Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Antibody Drug Conjugates Market 2017-2030 - Research and Markets

Research and Markets
Posted on: 16 Nov 17

The "Antibody Drug Conjugates Market (4th Edition) 2017-2030" report has been added to Research and Markets' offering.

The Antibody Drug Conjugates Market (4th Edition), 2017-2030' report provides a comprehensive study on the current landscape of ADCs, featuring an elaborate discussion on the future potential of this evolving market.

The field has captured the interest of several drug developers, both small and large companies. While more than half of these pipeline candidates are in the discovery / preclinical stages, around 10% of candidate therapies are presently in advanced stages (phase II and above); we anticipate the market to witness continued growth in the next 5-10 years.

Since the first approval of MYLOTARG in 2000 and its subsequent withdrawal in the year 2010, the ADC market has evolved considerably. In the last seven years, the market has witnessed an increasing interest from drug developers and healthcare investors alike. Post the commercialization of ADCETRIS in 2011 and KADCYLA in 2013, there was a temporary, but evident, decline in the popularity of ADCs.

This was attributed to the fact that no new ADC candidates were approved after 2013 and the focus had shifted to other novel therapies, such as immune checkpoint inhibitors and T-cell therapies. However, the recent approval of BESPONSA and re-approval of MYLOTARG has renewed the interest of stakeholders in the domain. This growing popularity and potential of ADCs can also be correlated with an exponential increase in the number of patents that have been filed; the cumulative number has increased from 1,395 patents in 2009 to 10,208 patents in the first half of 2017.

While there are close to 200 ADCs in clinical / preclinical stages of development, the field is currently going through a gradual transition. The industry is shifting from relying on conventional technologies to newer approaches for generating ADCs. This transition has paved way for several well-funded start-ups, which offer novel conjugation approaches, more potent warheads and modified linker technologies.

In addition, the ADCs are now being evaluated in combination with several other novel therapies, such as immune checkpoint inhibitors, epigenetic modulators and monoclonal antibodies.

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Market Overview

5. Key Opinion Leaders

6. Key Therapeutic Areas

7. Company And Drug Profiles

8. Partnerships And Collaborations

9. Venture Funding

10. Academic Grants

11. Combination Therapies

12. Novel Conjugation Technology Platforms

13. Assesment Of Non-Clinical Data, First In Human Dosing

14. Patent Analysis

15. Case Study: ADC Manufacturing

16. Market Forecast And Opportunity Analysis

17. SWOT Analysis

18. Conclusion

19. Interview Transcripts

20. Appendix 1: Tabulated Data

21. Appendix 2: List Of Companies And Organizations

For more information about this report visit

View source version on

Business Wire

Last updated on: 16/11/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.